

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Linzagolix for moderate to severe symptoms of  
uterine fibroids**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Final appraisal determination**

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

None raised during consultation.

It is noted that, in the final draft guidance, linzagolix is recommended in 'adults of reproductive age'. This specification of reproductive age is in line with the indications for use in the marketing authorisation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, see section 3.23.

**Approved by Associate Director (name):** Ian Watson

**Date:** 11/07/2024